Investors & Media

Press Releases



All Releases
View Summary TG Therapeutics, Inc. Announces Publication in Blood Describing a Novel Complimentary Mechanism of the PI3K-delta Inhibitor, TGR-1202
Oct 27, 2016
PDF 284.2 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces the Launch of the Phase 1/2 Study of TGR-1202 and Carfilzomib in Patients with Relapsed or Refractory Lymphoma
Oct 20, 2016
PDF 283.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Amends the GENUINE Phase 3 Clinical Trial to Accelerate Study Completion by Revising Primary Endpoint to Overall Response Rate
Oct 13, 2016
PDF 287.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call to Provide an Update on the GENUINE Phase 3 Trial
Oct 12, 2016
PDF 279.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the Ladenburg Thalmann 2016 Healthcare Conference
Sep 23, 2016
PDF 279.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Presentation of Data from a Phase Ib Clinical Trial of TG-1101 in Patients with Neuromyelitis Optica (NMO) at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Sep 16, 2016
PDF 286.2 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Clinical Data Presentation at the Upcoming 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Aug 31, 2016
PDF 285.5 KB Add to Briefcase
View Summary TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
Aug 26, 2016
PDF 283.8 KB Add to Briefcase
View Summary TG Therapeutics Announces Orphan Drug Designation for TGR-1202 for Treatment of Chronic Lymphocytic Leukemia
Aug 24, 2016
PDF 283.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Second Quarter 2016 Financial Results and Business Update
Aug 8, 2016
PDF 295.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2016 Financial Results and Business Update
Aug 4, 2016
PDF 280.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Data from TGR-1202 in Combination with Ibrutinib as well as Recaps Long-Term Safety and Efficacy Data of TGR-1202 in CLL and NHL at the 21st European Hematology Association Annual Congress
Jun 10, 2016
PDF 320.2 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the Jefferies 2016 Healthcare Conference
Jun 9, 2016
PDF 279.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces First Patient Enrolled in the Registration-Directed UNITY-DLBCL Phase 2b Trial
Jun 7, 2016
PDF 283.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety Profile and High Response Rates in CLL and NHL in Data Presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Jun 6, 2016
PDF 338.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the 52nd Annual Meeting of the American Society of Clinical Oncology
Jun 2, 2016
PDF 325.7 KB Add to Briefcase
View Summary TG Therapeutics Enters into a Global Collaboration to Develop and Commercialize Novel BET Inhibitors Developed by Jubilant Biosys for the Treatment of Hematological Malignancies
May 27, 2016
PDF 286.7 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 21st European Hematology Association Annual Congress
May 20, 2016
PDF 326.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Clinical Data Presentation at the Upcoming 52nd Annual Meeting of the American Society of Clinical Oncology
May 18, 2016
PDF 326.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces First Quarter 2016 Financial Results and Business Update
May 10, 2016
PDF 293.1 KB Add to Briefcase
Showing 81-100 of 228 Page: 1 2 3 4 5 6 7 8 9 ... 12  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase